SESIP Paves the Way for IoT Manufacturers to Meet New European Cybersecurity Rules
12.12.2024 09:00:00 CET | Business Wire | Press release
GlobalPlatform’s SESIP methodology (EN 17927) offers a streamlined, cost-effective security framework for connected devices and components to conform to the EU’s new Cyber Resilience Act
GlobalPlatform is calling for manufacturers of connected devices and components to adopt its “Security Evaluation Standard for IoT Platforms” (SESIP) methodology to demonstrate conformance with the European Union’s new Cyber Resilience Act (CRA), which comes into force this month. The CRA aims to strengthen and harmonize cybersecurity across the EU by creating a new legal framework for all products that connect to the internet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211681976/en/

(Graphic: Business Wire)
The enactment of the CRA puts into place mandatory cybersecurity rules that span the entire lifecycle of a digital product sold in the EU. The CRA was published in the Official Journal of the European Union last month and becomes law on December 11, 2024. Product manufacturers will have 36 months to fully comply with the legislation. The Act will eventually require all relevant products to comply with the rules in order to obtain the CE marking, a mandatory market requirement for issuing products in Europe.
As an internationally recognized standard for IoT security evaluation, SESIP is key to meeting the requirements mandated by the CRA. It provides manufacturers with a proven methodology for conducting security evaluations of software and hardware components across their products and supply chains. SESIP is recognized as a standard by CENELEC, the European Standardization Organization, as EN 17927. It also aligns with many other legislation and vertical certification schemes around the world, including the Cyber Trust Mark in the US.
The methodology is being used to certify components, platforms, and modules from a range of companies and is supported by a growing ecosystem of security providers, certification bodies (CBs), security laboratories, and other stakeholders. GlobalPlatform continues to support the growth and governance of the SESIP ecosystem. SGS Brightsight has recently been accredited as a SESIP CB following approval from the Spanish national accreditation body (ENAC), becoming the second SESIP CB after TrustCB.
“Industry support for SESIP is building at this critical juncture for IoT manufacturers operating in Europe,” said Gil Bernabeu, CTO of GlobalPlatform. “The Cyber Resilience Act is vital to protecting consumers and businesses by embedding security features into the heart of the connected devices we use every day, providing a cybersecurity framework that spans the design, development, and maintenance of digital products.
“However, this landmark legislation presents a range of compliance challenges for manufacturers of connected devices and the components used in these products,” continued Bernabeu. “SESIP simplifies conformity with the new regulations by providing a unified framework for comprehensive security evaluation, reducing cost, risk, and time to market. We look forward to expanding the SESIP ecosystem to help multiple industry sectors meet the requirements of the new European regulations. It will also enable international manufacturers to reuse their security evaluation investments to demonstrate conformance to non-European regulations.”
The SESIP methodology is already mapped to other standards and regulations such as ETSI, (EN 303645 / TS 103732), ISO/IEC (62443-4-2), RED (EN 18031), UNECE WP.29 (ISO/SAE 21434) and NIST (NIST 8259 / NIST 8425). It is also being used by schemes such as PSA Certified, and standardization bodies including the Car Connectivity Consortium and the Wireless Power Consortium. In addition to Europe, SESIP is being adopted around the world in key markets such as China, where an agreement was recently reached between GlobalPlatform and China’s National Financial Technology Certification Center (NFTC).
GlobalPlatform has a number of initiatives in place to help accelerate SESIP adoption. A training program has been launched and available for any interested party. It has also launched the SESIP Adopters community to give non-members the ability to keep up to date with relevant technical documents and showcase certified SESIP products.
For more information on SESIP please visit: https://globalplatform.org/sesip/
About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices, which deliver end-to-end security, privacy, simplicity, and convenience to users. It achieves this by providing standardized technologies and certifications that empower technology and service providers to develop, certify, deploy, and manage digital services and devices in line with their business, security, regulatory and data protection needs. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected and IoT devices.
GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.
globalplatform.org | Twitter / X | LinkedIn | YouTube | GitHub | WeChat
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211681976/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom